Profusa, Inc. $(PFSA)$, a digital health company specializing in continuous biochemical monitoring technology, has announced a Letter of Intent to establish a distribution agreement in Spain for its Lumee Oxygen platform. The agreement is with Dismeval, S.L., a Spanish distributor known for its expertise in medical and surgical equipment across Spain, including the Canary and Balearic Islands. This partnership represents Profusa's initial steps towards building a strong distribution network in Europe. The company aims to introduce its innovative real-time personal healthcare technologies to the clinical community, targeting a $10.5 billion global market for its tissue oxygen technology. This market includes applications in peripheral artery disease, chronic wounds, and critical limb ischemia, addressing a significant clinical need in Europe with over 300,000 endovascular procedures annually.